Imanol Arozarena, principal investigator of the Cancer Signalling Unit of Navarrabiomed, leads one of the three projects awarded in the IdiSNA intramural call.

The CHOLANGIOMEL project, in which CIMA researchers collaborate, is one of the three projects awarded in the IdiSNA intramural call. It will be developed over the next two years and will receive a grant of € 25,000 for the study of lipid metabolism as a therapeutic target against metastatic cancer. 
According to Imanol Arozarena, as published in the Diario de Noticias "this project is going to focus on studying cholangiocarcinoma models, on whether drugs that block the tumour’s ability to use fats can prevent those cholangiocarcinoma tumour cells from forming metastases in the viscera, which is ultimately what kills patients." It is also about "generating more knowledge and better understanding why tumours use fats to form metastases" and, secondly, to achieve drug therapy that attempts to prevent the onset of metastases.

Lab manufacturing mini heart valves

Another project involving Navarrabiomed will obtain financing through the one granted in the IdiSNA intramural call. It is the study of the influence of anti-cancer treatments on valvulopathies that seeks to manufacture mini heart valves in the laboratory to study what effects chemotherapy and radiotherapy treatments produce. It is led by Manuel Mazo Vega, from the University of Navarra Clinic/University of Navarra and has the collaboration of Navarrabiomed researcher Natalia López Andrés, head of the Navarrabiomed translational Cardiology unit. 

Read this news in Diario de Noticias